This week, we’ll start off with a report that showed that ibrutinib may help to protect patients infected with COVID-19 from pulmonary injury due to the disease. Next, we’ll move onto a report from the AACR Virtual Annual Meeting on talazoparib in patients with locally advanced or metastatic HER2-negative germline BRCA­-mutated breast cancer. Lastly, we’ll review the FDA’s approval of niraparib for patients with advanced ovarian cancer.

Coverage of stories discussed this week on ascopost.com:

Potential Protective Effect of Ibrutinib Against Pulmonary Injury in Patients With COVID-19

AACR 2020: Final Overall Survival Results From the Phase III EMBRACA Trial

FDA Approves Niraparib as Maintenance Therapy for Advanced Ovarian Cancer